search
Back to results

Deep Brain Stimulation of the Bilateral Nucleus Accumbens for Patients With Methadone Maintenance Treatment

Primary Purpose

Addiction Opiate

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Bilateral surgical implantation of DBS system to Nucleus Accumbens
Sponsored by
Ruijin Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Addiction Opiate focused on measuring Nucleus Accumbens, Deep brain stimulation, Methadone

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • MINI diagnosis of substance dependence;
  • Proficiency in Mandarin language;
  • Failure to detox more than three times;
  • Long-term methadone maintenance treatment;
  • Capacity to provide informed consent (understanding of the study purpose and methods);

Exclusion Criteria:

  • Schizophrenia(MINI diagnosis);
  • Antisocial personality disorder(MINI diagnosis);
  • Contraindications of a MRI-examination, e.g. implanted cardiac pacemaker/heart defibrillator;
  • Severe cognitive impairments(MoCA ≤ 22);
  • Enrollment in other clinical trials;
  • Stereotactic respectively neurosurgical intervention in the past;
  • Contraindications of stereotactic intervention, e.g. increased bleeding disposition, cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic vascular diseases);
  • Serious or instable organic diseases (e.g. instable coronal heart disease);
  • Tested positively for HIV;
  • Pregnancy and/or lactation;
  • Epilepsy or other severe brain trauma or neurological impairments;

Sites / Locations

  • Shanghai Ruijin Hospital Functional NeurosurgeryRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

DBS

Arm Description

All subjects will undergo bilateral surgical implantation of DBS system in the Nucleus Accumbens. The DBS system will be active at two days after surgery.

Outcomes

Primary Outcome Measures

Changes in Methadone dose
The volume of daily methadone the patients used.

Secondary Outcome Measures

Hamilton Depression Scale(HAMD-17)
17 items, Total scores<7: normal; 7<Total scores≤17: possible depression; 17<Total scores≤24: definite depression; Total score>24: severe depression
Hamilton Anxiety Scale (HAMA)
14 items, Total scores<6: normal; 7<Total scores≤14: possible anxiety; 14<Total scores≤21:definite anxiety; Total score>21: severe anxiety
Young Manic Rating Scale (YMRS)
The Young Mania Rating Scale (YMRS) is one of the most frequently utilized rating scales to assess manic symptoms. The scale has 11 items and is based on the patient's subjective report of his or her clinical condition.
Monitoring of Side Effects Scale (MOSES)
To evaluate side effects. The higher score means more severity of side effects.
Changes in Subjective Opiate Withdrawal Scale(SOWS)
Subjective Opiate Withdrawal Scale is a 16-item self-reported scale assessing severity of opiate withdrawal. Each item is rated on a 5-point Likert scale, ranging form 0(not at all) to 4(extremely).
Obsessive compulsive drug use scale(OCDUS)
Obsessive compulsive drug use scale is a 13-item self-rating scale measuring opiate craving. The total score ranges from 0 to 52. The higher score indicates stronger carving.
The MOS item short from health survey (SF-36)
36 items. To evaluate the quality of life and the higher score indicates better quality of life.
World Health Organization Quality of Life-BREF (WHO-BREF)
26 items. The higher score means the better quality of life.
Fagerstrom Test for Nicotine Dependence assessment (FTND)
To evaluate Nicotine Dependence. The higher of scores indicates higher level of Nicotine Dependence
Beck depression inventory(BDI)
The BDI contains 21 questions, each answer scored on a scale value of 0 to 3. 0-13: minimal depression;14-19:mild depression; 20-28:moderate depression; and 29-63:severe depression. Higher total score indicate more severe depressive symptoms.
Beck anxiety inventory(BAI)
The BAI contains 21 questions, each answer scored on a scale value of 0 to 3. 0-21: mild anxiety;22-35: moderate anxiety;36-63:severe anxiety. Higher total score indicate more severe anxiety symptoms.
Perceived stress scale(PSS-10)
The PSS-10 is a classic stress assessment instrument. Each item is rated on a 5-likert scale ranging form 0(never) to 4(often). Higher score indicate more severity of stress symptom.
Twenty Item Positive and Negative Affect Schedule (PANAS)
The PANAS contains two subscales: positive and negative subscale. Each item is rated on a 5-likert scale ranging from 1(Not at all) to 5(severely, it bothered me a lot).
Work and Social Adjustment Scale(WSAS)
Self-rated scale. The maximum score of the WSAS is 40, lower scores are better.
Cognitive performance
Cognitive performance is measured by a series of tasks which include stop signal task, paired associated memory, spatial working memory, stocking of Cambridge, intra-extra dimensional set shift, Bart, Beads, Delay discounting task, model-based and model-free task, avoid-approach task, dot-probe task, drug rating task.
Brain activity
PET(Positron Emission Tomography) or fMRI(functional Magnetic Resonance Imaging) are used in this study.

Full Information

First Posted
May 14, 2019
Last Updated
January 7, 2020
Sponsor
Ruijin Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03952455
Brief Title
Deep Brain Stimulation of the Bilateral Nucleus Accumbens for Patients With Methadone Maintenance Treatment
Official Title
Deep Brain Stimulation of the Bilateral Nucleus Accumbens for Patients With Methadone Maintenance Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Unknown status
Study Start Date
May 13, 2019 (Actual)
Primary Completion Date
June 1, 2021 (Anticipated)
Study Completion Date
June 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ruijin Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Methadone maintenance treatment (MMT) is one of the main forms of treatments for opioid dependence. Despite its effectiveness and widespread use, people will experience withdrawal if daily dose is insufficient or missed, promoting reluctance to attempt detoxification. In addition, methadone is a full opioid agonist which can induce respiratory depression or sedation without ceiling level, so overdose usage can be fatal. Hence, an alternative therapy is needed to completely reduce the carving for drugs and to relieve the negative affective sate caused by withdrawal. Deep brain stimulation (DBS) is a reasonable treatment approach for addiction. Since 2009 the first case report emerged, the nucleus accumbens (NAc) is still the only brain target to be investigated in clinical case series of DBS for alcohol and heroin addiction. This research will mainly investigate the effectiveness and safety of NAc-DBS for patients with methadone maintenance treatment. The investigators will also explore the influence of NAc-DBS on brain activity and cognition.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Addiction Opiate
Keywords
Nucleus Accumbens, Deep brain stimulation, Methadone

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
DBS
Arm Type
Experimental
Arm Description
All subjects will undergo bilateral surgical implantation of DBS system in the Nucleus Accumbens. The DBS system will be active at two days after surgery.
Intervention Type
Procedure
Intervention Name(s)
Bilateral surgical implantation of DBS system to Nucleus Accumbens
Intervention Description
We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
Primary Outcome Measure Information:
Title
Changes in Methadone dose
Description
The volume of daily methadone the patients used.
Time Frame
Baseline (preoperative),1 month, 3 months,6 months,9 months, 12 months
Secondary Outcome Measure Information:
Title
Hamilton Depression Scale(HAMD-17)
Description
17 items, Total scores<7: normal; 7<Total scores≤17: possible depression; 17<Total scores≤24: definite depression; Total score>24: severe depression
Time Frame
Baseline(preoperative),1 month, 3 months, 6 months, 9 months, 12 months
Title
Hamilton Anxiety Scale (HAMA)
Description
14 items, Total scores<6: normal; 7<Total scores≤14: possible anxiety; 14<Total scores≤21:definite anxiety; Total score>21: severe anxiety
Time Frame
Baseline(preoperative),1 month, 3 months, 6 months,9 months, 12 months
Title
Young Manic Rating Scale (YMRS)
Description
The Young Mania Rating Scale (YMRS) is one of the most frequently utilized rating scales to assess manic symptoms. The scale has 11 items and is based on the patient's subjective report of his or her clinical condition.
Time Frame
Baseline(preoperative),1 month, 3 months, 6 months,9 months, 12 months
Title
Monitoring of Side Effects Scale (MOSES)
Description
To evaluate side effects. The higher score means more severity of side effects.
Time Frame
Baseline(preoperative),1 month, 3 months, 6 months,9 months, 12 months
Title
Changes in Subjective Opiate Withdrawal Scale(SOWS)
Description
Subjective Opiate Withdrawal Scale is a 16-item self-reported scale assessing severity of opiate withdrawal. Each item is rated on a 5-point Likert scale, ranging form 0(not at all) to 4(extremely).
Time Frame
Baseline(preoperative),1 month, 3 months, 6 months,9 months, 12 months
Title
Obsessive compulsive drug use scale(OCDUS)
Description
Obsessive compulsive drug use scale is a 13-item self-rating scale measuring opiate craving. The total score ranges from 0 to 52. The higher score indicates stronger carving.
Time Frame
Baseline(preoperative),1 month, 3 months, 6 months,9 months, 12 months
Title
The MOS item short from health survey (SF-36)
Description
36 items. To evaluate the quality of life and the higher score indicates better quality of life.
Time Frame
Baseline(preoperative),1 month, 3 months,6 months,9 months, 12 months
Title
World Health Organization Quality of Life-BREF (WHO-BREF)
Description
26 items. The higher score means the better quality of life.
Time Frame
Baseline(preoperative),1 month, 3 months,6 months,9 months, 12 months
Title
Fagerstrom Test for Nicotine Dependence assessment (FTND)
Description
To evaluate Nicotine Dependence. The higher of scores indicates higher level of Nicotine Dependence
Time Frame
Baseline(preoperative),1 month, 3months,6months,9 months, 12 months
Title
Beck depression inventory(BDI)
Description
The BDI contains 21 questions, each answer scored on a scale value of 0 to 3. 0-13: minimal depression;14-19:mild depression; 20-28:moderate depression; and 29-63:severe depression. Higher total score indicate more severe depressive symptoms.
Time Frame
Baseline(preoperative),1 month, 3months,6months,9 months, 12 months
Title
Beck anxiety inventory(BAI)
Description
The BAI contains 21 questions, each answer scored on a scale value of 0 to 3. 0-21: mild anxiety;22-35: moderate anxiety;36-63:severe anxiety. Higher total score indicate more severe anxiety symptoms.
Time Frame
Baseline(preoperative),1 month, 3months,6months,9 months, 12 months
Title
Perceived stress scale(PSS-10)
Description
The PSS-10 is a classic stress assessment instrument. Each item is rated on a 5-likert scale ranging form 0(never) to 4(often). Higher score indicate more severity of stress symptom.
Time Frame
Baseline(preoperative),1 month, 3months,6months,9 months, 12 months
Title
Twenty Item Positive and Negative Affect Schedule (PANAS)
Description
The PANAS contains two subscales: positive and negative subscale. Each item is rated on a 5-likert scale ranging from 1(Not at all) to 5(severely, it bothered me a lot).
Time Frame
Baseline(preoperative),1 month, 3months,6months,9 months, 12 months
Title
Work and Social Adjustment Scale(WSAS)
Description
Self-rated scale. The maximum score of the WSAS is 40, lower scores are better.
Time Frame
Baseline(preoperative),1 month, 3months,6months,9 months, 12 months
Title
Cognitive performance
Description
Cognitive performance is measured by a series of tasks which include stop signal task, paired associated memory, spatial working memory, stocking of Cambridge, intra-extra dimensional set shift, Bart, Beads, Delay discounting task, model-based and model-free task, avoid-approach task, dot-probe task, drug rating task.
Time Frame
Baseline(preoperative),6 months,12 months
Title
Brain activity
Description
PET(Positron Emission Tomography) or fMRI(functional Magnetic Resonance Imaging) are used in this study.
Time Frame
Baseline(preoperative), 6 months,12 months
Other Pre-specified Outcome Measures:
Title
Barratt impulsiveness scale
Description
The Barratt Impulsiveness Scale is a questionnaire designed to assess the personality/behavioral construct of impulsiveness which is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. It has three 2nd order facets which are attentional, motor and non-planning. Each facet has 10 items. Higher score means greater impulsivity.
Time Frame
Baseline(preoperative)
Title
UPPS-P impulsive behavior scale
Description
The UPPS-P Impulsive Behavior Scale is a 59-item questionnaire assessing impulsive personality traits. Each item is rated on a 4-point scale ranging from 1 (agree strongly) to 4 (disagree strongly) to indicate subject's agreement with statements. This scale includes the following five subscales: negative urgency (NU), lack of premeditation (LPM), lack of perseverance (LPS), sensation seeking (SS) and positive urgency (PU). Higher score represents a greater level of impulsivity.
Time Frame
Baseline(preoperative)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: MINI diagnosis of substance dependence; Proficiency in Mandarin language; Failure to detox more than three times; Long-term methadone maintenance treatment; Capacity to provide informed consent (understanding of the study purpose and methods); Exclusion Criteria: Schizophrenia(MINI diagnosis); Antisocial personality disorder(MINI diagnosis); Contraindications of a MRI-examination, e.g. implanted cardiac pacemaker/heart defibrillator; Severe cognitive impairments(MoCA ≤ 22); Enrollment in other clinical trials; Stereotactic respectively neurosurgical intervention in the past; Contraindications of stereotactic intervention, e.g. increased bleeding disposition, cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic vascular diseases); Serious or instable organic diseases (e.g. instable coronal heart disease); Tested positively for HIV; Pregnancy and/or lactation; Epilepsy or other severe brain trauma or neurological impairments;
Facility Information:
Facility Name
Shanghai Ruijin Hospital Functional Neurosurgery
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200025
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chencheng Zhang, MD
Phone
+086-18217122884
Email
i@cczhang.org
First Name & Middle Initial & Last Name & Degree
Yingying Zhang, MSc
Phone
+086-17602137369
Email
zhyy019@126.com

12. IPD Sharing Statement

Citations:
PubMed Identifier
23227826
Citation
Muller UJ, Voges J, Steiner J, Galazky I, Heinze HJ, Moller M, Pisapia J, Halpern C, Caplan A, Bogerts B, Kuhn J. Deep brain stimulation of the nucleus accumbens for the treatment of addiction. Ann N Y Acad Sci. 2013 Apr;1282:119-28. doi: 10.1111/j.1749-6632.2012.06834.x. Epub 2012 Dec 10.
Results Reference
background
PubMed Identifier
23337942
Citation
Kuhn J, Moller M, Treppmann JF, Bartsch C, Lenartz D, Gruendler TO, Maarouf M, Brosig A, Barnikol UB, Klosterkotter J, Sturm V. Deep brain stimulation of the nucleus accumbens and its usefulness in severe opioid addiction. Mol Psychiatry. 2014 Feb;19(2):145-6. doi: 10.1038/mp.2012.196. Epub 2013 Jan 22. No abstract available.
Results Reference
background
PubMed Identifier
27145161
Citation
Muller UJ, Sturm V, Voges J, Heinze HJ, Galazky I, Buntjen L, Heldmann M, Frodl T, Steiner J, Bogerts B. Nucleus Accumbens Deep Brain Stimulation for Alcohol Addiction - Safety and Clinical Long-term Results of a Pilot Trial. Pharmacopsychiatry. 2016 Jul;49(4):170-3. doi: 10.1055/s-0042-104507. Epub 2016 May 4.
Results Reference
background

Learn more about this trial

Deep Brain Stimulation of the Bilateral Nucleus Accumbens for Patients With Methadone Maintenance Treatment

We'll reach out to this number within 24 hrs